Trial Profile
Comparing efficacy of Left ventricular assist device (LVAD) therapy with Levosimendan in patient eligible for heart transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Apr 2018
Price :
$35
*
At a glance
- Drugs Levosimendan (Primary)
- Indications Acute heart failure; Heart failure
- Focus Therapeutic Use
- 27 Apr 2018 New trial record
- 14 Apr 2018 Results presented at the 38th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation